2020
Should Angiotensin-Converting Enzyme Inhibitors ever Be Used for the Management of Hypertension?
Turner JM, Kodali R. Should Angiotensin-Converting Enzyme Inhibitors ever Be Used for the Management of Hypertension? Current Cardiology Reports 2020, 22: 95. PMID: 32648000, PMCID: PMC7344347, DOI: 10.1007/s11886-020-01352-8.Commentaries, Editorials and LettersMeSH KeywordsAngiotensin Receptor AntagonistsAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsHumansHypertensionRenin-Angiotensin SystemConceptsAngiotensin receptor blockersACE inhibitorsEnzyme inhibitorsReceptor blockersSimilar efficacyAngiotensin converting enzyme (ACE) inhibitorsAdverse effectsAnti-hypertensive medicationsManagement of hypertensionUse of ARBGreater side effectsEqual efficacySide effectsClinical scenariosRecent FindingsInClinical settingARBsPrevious trialsEfficacyHypertensionBlockersInhibitorsTrialsAdvantageous effectsMedications
2016
We Avoid RAAS Inhibitors in PD Patients with Residual Renal Function
Turner JM. We Avoid RAAS Inhibitors in PD Patients with Residual Renal Function. Seminars In Dialysis 2016, 29: 265-267. PMID: 27061273, DOI: 10.1111/sdi.12488.Commentaries, Editorials and LettersMeSH KeywordsAngiotensin Receptor AntagonistsAngiotensin-Converting Enzyme InhibitorsGlomerular Filtration RateHumansKidney Failure, ChronicNephrologyPeritoneal DialysisRenin-Angiotensin SystemConceptsResidual renal functionPeritoneal dialysisRAAS inhibitorsRenal functionAngiotensin receptor blockersGlomerular filtration rateRAAS blockadeAldosterone systemReceptor blockersNephrotoxic agentsPD patientsPD populationFiltration rateModality failureUltrafiltration failureEnzyme inhibitorsPatientsPeritoneal membraneMorphologic changesInhibitorsMortalityCliniciansAnuriaAngiotensinFailure